Potential Vaccines and Post-Exposure Treatments for Filovirus Infections

Brian M. Friedrich 1,†, John C. Trefry 1,†, Julia E. Biggins 1, Lisa E. Hensley 2, Anna N. Honko 1, Darci R. Smith 1 and Gene G. Olinger 1,*

1 United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, MD 21702, USA; E-Mails: brian.m.friedrich.ctr@us.army.mil (B.M.F.); john.c.trefry.ctr@us.army.mil (J.C.T.); julia.biggins@us.army.mil (J.E.B.); anna.honko@us.army.mil (A.N.H.); darci.smith1@us.army.mil (D.R.S.)

2 United States Food and Drug Administration (FDA), Medical Science Countermeasures Initiative (McMi), 10903 New Hampshire Avenue, Silver Spring, MD 20901, USA; E-Mail: lisa.hensley@fda.hhs.gov

† These authors contributed equally to this work.

* Author to whom correspondence should be addressed; E-Mail: Gene.olinger@us.army.mil; Tel.: +1-301-619-8581.

Received: 20 July 2012; in revised form: 31 August 2012 / Accepted: 4 September 2012 / Published: 21 September 2012

Abstract: Viruses of the family Filoviridae represent significant health risks as emerging infectious diseases as well as potentially engineered biothreats. While many research efforts have been published offering possibilities toward the mitigation of filoviral infection, there remain no sanctioned therapeutic or vaccine strategies. Current progress in the development of filovirus therapeutics and vaccines is outlined herein with respect to their current level of testing, evaluation, and proximity toward human implementation, specifically with regard to human clinical trials, nonhuman primate studies, small animal studies, and in vitro development. Contemporary methods of supportive care and previous treatment approaches for human patients are also discussed.

Keywords: filovirus; Ebola; ebolavirus; Marburg virus; marburgvirus; vaccines; post-exposure treatments; clinical trials; non-human primates; animal models
1. Introduction

The family Filoviridae includes two accepted genera, *Ebolavirus* and *Marburgvirus*. The genus *Ebolavirus* includes five species (each represented by a single virus): *Zaire ebolavirus* (Ebola virus, EBOV), *Sudan ebolavirus* (Sudan virus, SUDV), *Reston ebolavirus* (Reston virus, RESTV), *Tai Forest ebolavirus* (Tai Forest virus, TAFV), and *Bundibugyo ebolavirus* (Bundibugyo virus, BDBV). The genus *Marburgvirus* includes a single species, *Marburg marburgvirus*, which has two members: Marburg virus (MARV) and Ravn virus (RAVV) [1,2]. In 1967, the first cases of filoviral infection were documented in three simultaneous outbreaks in West Germany and Yugoslavia. The virus responsible for the outbreaks was named “Marburg virus” after the German city of Marburg in which it was first recognized [3,4]. From documented instances of infection, it seems that the members of the filovirus genera may exist in quite opposite climates of Africa with marburgvirus infections occurring more frequently in the dry woodlands, while ebolavirus infections occur more frequently in rain forests [5]. More than 40 years of effort have focused on the search for the reservoir of these viruses in Africa, and while the search is still ongoing, recent evidence indicates that bats may be reservoirs for both marburgviruses and ebolaviruses [1,6–11]. However, the recent outbreak of RESTV in domestic pigs in the Philippines demonstrated the potential for animals other than primates and bats to be infected and potentially spread or amplify outbreaks [12].

Filoviruses are named for their long, filamentous shape which can been seen on the order of micrometers in length, while their width is more narrow (usually around 80 nm) with little fluctuation [13]. Contained within this filamentous virus is a single, 19-kb negative-sense RNA genome that encodes seven proteins [14,15]. The seven filoviral proteins are the glycoprotein (GP), the polymerase (L), the nucleoprotein (NP), a secondary matrix protein (VP24), the transcriptional activator (VP30), the polymerase cofactor (VP35), and the matrix protein (VP40) [16,17]. Homotrimers of the viral GP cover the surface of the virion, and this viral GP is believed to be the sole host attachment factor for filoviruses [6,18]. Candidates for filoviral receptor and co-factors include transferrin, DC-SIGN, TIM-1, and NPC1 [16,19–22]. After entry, filoviruses replicate their genomes and viral proteins in the cytoplasm using a RNA-dependent RNA-polymerase which is carried in with the virus.

Wild-type filovirus infection has been associated with severe case fatality rates in humans, as high as 90% [15]. In humans, filovirus infection is characterized by an abrupt onset of flu-like illness, after an initial incubation period of 2–21 days. Following this initial illness, signs and symptoms of disease include anorexia, nausea, vomiting, chest pain, cough, edema, postural hypotension, neurologic complications, petechiae, and mucosal hemorrhage. There have also been several observed wild-type filovirus outbreaks among great apes in Africa that have demonstrated similarly high mortality rates [23]. In an effort to create cost and time-effective models of filoviral disease for the development of vaccines and therapeutics, small animals, such as mice and guinea pigs, are often used. However, these animals usually demonstrate significant resistance to wild-type filovirus infection, and only demonstrate mortality rates similar to primates when the filovirus in question has been adapted to the model species [24]. Due to the difficulties in evaluating wild-type filovirus infection in small animals and the generally high level of immune protection correlates derived from non-human primate (NHP) models of infection, therapeutics and vaccines are ultimately evaluated in NHP species for efficacy against filovirus. Of the NHP models available for filovirus study, rhesus and cynomolgus macaques...
have been the most highly characterized and utilized for therapeutic and vaccine development, respectively. However, the starting point of vaccine and therapeutic development remains small animal models due to the cost, ethical, and time-associated benefits [17]. This review will highlight the current research into filovirus vaccines and therapeutics.

2. Current Treatments

2.1. Supportive Care

The current clinical standard for filoviral infection is supportive care as there are currently no FDA-approved treatment strategies. Supportive care consists of oral fluid rehydration, oral medication, nutritional supplementation, and psychosocial support [25]. Nasogastric feeding tubes and i.v. administration of both fluids and medication are increasingly considered supportive care where possible during outbreak scenarios to prevent dehydration and facilitate support of blood pressure [25,26]. However, given the limited equipment and laboratory support during outbreaks, care must be taken to prevent overaggressive fluid administration [27]. Fluid replacement was evaluated briefly in rhesus macaques, and while there was no significant benefit to survival, a less severe renal compromise was observed [28]. While supportive care may (or may not) reduce the overall case fatality rate in humans, the true impact of simple interventions such as fluid management has yet to be fully evaluated and the potential for benefit in combination with direct antiviral measures has yet to be assessed [29].

2.2. Immunotherapy

Treatment of filovirus infection with passive transfer of antibodies is an attractive therapy. While there have been conflicting results in vitro, in animals, and in humans, recent breakthroughs have solidified the potential for this strategy of intervention. In addition, there have been a number of immunotherapies developed for other agents, such as respiratory syncytial virus (RSV), which can provide potential roadmaps or precedence to facilitate the advancement of these products through the necessary regulatory hurdles [30,31]. Transfer of immune serum for the treatment of filovirus infection in humans has previously been attempted. However, interpretation of these results has been cautious due to the study conditions as well as the uncertainty of the disease stage at which the individuals were treated [6]. As a result, much attention has focused on animal studies evaluating candidate products. While many of the early studies in mice and guinea pigs were successful, these successes did not translate to NHP studies and tempered the enthusiasm for further evaluation of candidate products. [6,32–35]. When similar passive transfer strategies were attempted in NHPs, viremia onset and outward signs of disease were reduced, but the treatment did not affect survivorship [36–38]. In addition, the suggestion that antibodies could enhance filovirus infections in vitro caused further concern [39–41].

However, recently a series of experiments have made researchers, developers, and funding agencies reconsider the potential of this category of products for filoviruses. Both polyclonal and monoclonal passive therapies have been shown to be efficacious in rodents for filovirus infection [42–44]. Furthermore, evidence of enhancing antibodies exists in the antibody response to EBOV [38]. More recent studies have demonstrated protection in macaques with polyclonal and monoclonal
passive therapy [45–47]. These sources of monoclonal antibodies have ranged from murine monoclonal antibodies to recombinant-derived cloned human monoclonal antibodies from survivors of filovirus infection [37,43].

Development of new antibodies to be used for post-exposure treatment is on-going. In one study, an antibody (13F6) targeting the EBOV GP mucin-like domain was generated and subsequently shown to protect 100% of mice against a lethal EBOV challenge when given 2 days post-exposure [44]. This antibody was then modified to generate h-13F6, a human recombinant antibody. This human recombinant antibody also significantly protected mice against a lethal challenge of EBOV [48]. In another method, a recombinant VSVΔG/EBOVGP was used to generate a total of 8 monoclonal antibodies which were subsequently characterized. All 8 monoclonal antibodies improved survival rate of mice (33%–100%) against a high-dose lethal challenge by mouse-adapted EBOV [49]. Another antibody, KZ52, was isolated from the bone marrow of a human survivor of EBOV infection and is specific for the complex of GP1 and GP2 [50]. KZ52 neutralized EBOV in vitro and offered protection from lethal EBOV challenge in a rodent model [43], but was non-protective in NHPs [37].

3. Vaccines

3.1. Vaccines in Human Clinical Trials – Summarized in Table 1

3.1.1. DNA Vaccines

The first clinical trials involving filovirus vaccines were based off of plasmids expressing EBOV NP and GP as well as SUDV GP [51]. This strategy proved safe in 27 subjects involved with phase I testing. However, the prime/boost DNA vaccine strategy covering four separate plasmid doses administered three times each was ineffective at creating durable immunity as evidenced by the near non-existent antibody titer in these subjects after 1 year [51]. While clinical trials with this vaccine have halted, it may be possible that this strategy can supplement another vaccine technology in a prime/boost capacity.

Table 1. Vaccines in Clinical Trials or Effective in Non-human Primates. Comparison of current vaccine candidates at the highest levels of development, either in human clinical trials or those that have shown promise in non-human primates (NHPs). Also listed are the afforded levels of immunization/protection, the type of vaccine used to induce immunity and the vaccination paradigm used to achieve the listed results.

| Vaccine          | Type                  | Mechanism                      | Species Tested | Efficacy               | Strategy                      |
|------------------|-----------------------|--------------------------------|----------------|------------------------|-------------------------------|
| DNA Vaccine      | DNA vaccine           | Adaptive Immune Response        | Cynomolgus macaque | 100% EBOV              | 3 i.m. injections, 4 weeks apart |
| Ebola rAd5 vaccine | Vector-based vaccine | Adaptive Immune Response        | Cynomolgus macaque | 100% EBOV              | Single i.m. injection         |
| CadVax-based EBO7 vaccine | Vector-based vaccine, blend of 4 vectors expressing 5 different genes | Adaptive Immune Response | Cynomolgus macaque | 100% EBOV 100% SUDV 100% MARV | 2 i.m. injections, 9 weeks apart |
3.1.2. Ebola rAd5 Replication Defective Vaccine

While no vaccines or therapeutics are currently licensed for use by the FDA, phase I clinical trial safety tests have been performed on one particular platform for an EBOV vaccine. This vaccine is based on a replication deficient, recombinant adenovirus serotype 5 (rAd5) vector genetically engineered to carry the genes for EBOV glycoprotein (GP (Z)) and SUDV glycoprotein (GP (S/G)). As a common human pathogen, this vector vaccine utilized the broad-tropism of the adenovirus vector to infect cells and once inside the inserted ebolavirus glycoproteins are expressed. Upon expression of these inserted ebolavirus genes, the host immune system will recognize them as foreign and mount a response against them. The advancement of this vaccine technology to phase I trials manifested from its ability to provide 100% protection among cynomolgus macaques vaccinated 28–35 days prior to challenge and its ability to generate potent humoral and cell-mediated immune responses [52,53].

In the clinical trial participants remained asymptomatic after a single vaccination with either $2 \times 10^9$ or $2 \times 10^{10}$ viral particles [54]. Furthermore, for both doses of the vaccine significant antibody titers were observed at 4 weeks post-vaccination with 100% and 55% of participants receiving $2 \times 10^{10}$ viral particles being positive for GP (S/G) and GP (Z), respectively. Significant antibody titers were observed again at 48 weeks post-vaccination and, while decreased from 4 weeks, demonstrated the potential durability of this vaccine over time [54]. T-cell activation was also examined for these individuals and found to directly correlate with the dose administered, but to a lesser extent than the previously mentioned antibody response. CD4$^+$ activation was observed with greater frequency than

| Vaccine                          | Type                                      | Mechanism         | Species Tested | Efficacy                      | Strategy                          |
|----------------------------------|-------------------------------------------|-------------------|----------------|-------------------------------|-----------------------------------|
| VSVΔG/EBOV-GP vaccine            | Vector-based vaccine, can be single vector or multiple vector blend, replication competent | Adaptive Immune Response | Rhesus macaque | 100% EBOV 100% SUDV 100% TAFV 75% BDBV 100% MARV | Single i.m. injection |
| VEE Replicon Particle (VRP) vaccine | Vector-based vaccine, single round replication | Adaptive Immune Response | Cynomolgus macaque | 100% MARV | 3 i.m. injections, 4 weeks apart |
| HPIV-3 vaccine                   | Vector-based vaccine, replication competent | Adaptive Immune Response | Rhesus macaque | 100% EBOV | 2 i.n./i.t. inoculation, 4 weeks apart |
| NDV-GP                           | Vector-based vaccine, replication competent | Adaptive Immune Response | Rhesus macaque-immune response evaluation (not challenged) | Less immunogenic than HPIV-3 but could augment HPIV-3 in prime/boost strategy | 2 i.n./i.t. inoculation, 4 weeks apart |
| VLP                              | Non-replicating virus particle vaccine    | Adaptive Immune Response | Cynomolgus macaque | 100% EBOV 100% MARV | 3 i.m. injections, 6 weeks apart |
CD8+ activation in those receiving the vaccine. Importantly, these results were obtained in the context of significant pre-existing immunity to Ad5 as pre-entry evaluation of antibody titers revealed that 50% of participants were positive against Ad5, showing that pre-existing immunity to Ad5 still resulted in protection against EBOV [54]. While this study shows great promise, further development and additional studies in NHPs and humans are needed.

3.2. Vaccines Effective in NHPs – Summarized in Table 1

3.2.1. Other Adenovirus Vector Vaccines

In addition to the adenovirus platform in clinical trials, additional variations of the rAd5 vaccine are also in development and have been evaluated in NHP models. Based on the adenovirus vector platform, the complex adenovirus (CAdVax) technology substantially increased the genetic payload capacity of the vector, up to 7 kB. Additionally, this strategy involved the blending of four separate vectors expressing the glycoproteins of EBOV, SUDV, and MARV along with the nucleoproteins of EBOV and MARV. When administered in a prime/boost strategy, this technology offered 100% protection against EBOV, SUDV, and MARV [55]. Another variation of the CAdVax system designed to express modified EBOV glycoprotein and SUDV glycoprotein was effective in protecting against both parenteral and aerosol challenge when administered in a prime/boost strategy [56]. Both implementations of the CAdVax technology demonstrated significant antibody titers.

Further improvement upon the adenovirus-based EBOV vaccine technology is ongoing. Richardson et al. reformatted the genetic insert for the vector which included the addition of a cytomegalovirus (CMV)-chicken β-actin hybrid promoter, optimized codons and a consensus Kozak sequence [57]. These improvements led to three- to seven-fold increases in EBOV glycoprotein expression. Neutralizing antibody titers were found at doses as low as $10^4$ infectious forming units (IFU) with comparable titers requiring $10^7$ IFU of the unmodified vaccine in mice. These modifications demonstrated 100% protection of mice at doses two orders of magnitude lower than the unmodified vaccine. Interestingly, at 30 min post-challenge, the modified Ad-CMVZGP/Ad-CAGoptZGP offered 100% protection compared to the 22% protection of mice offered from the original vaccine [57]. This vector format has also recently showed promise when administered sublingually in mice, therefore eliminating the complexities of parenteral administration such as the necessity for sterile tools, aseptic chemicals, and the risks of potential blood-borne pathogen exposure [58].

While this adenovirus vector vaccine technology is promising, demonstrations that pre-existing immunity to the Ad5 vector depressed the desired immune response may impede its implementation. In efforts to circumvent issues of pre-existing immunity to Ad5, Geisbert et al. sought out a less prevalent serovariation [59]. In their study, a heterologous prime/boost strategy with recombinant adenovirus serotypes 26 and 35 carrying GP (Z) and GP (S/G) demonstrated complete protection among NHPs. Each of these vectors was capable of stimulating humoral and cell-mediated immune responses in the context of NHPs pre-vaccinated with rAd5 as evidenced by antibody titers reaching an order of magnitude above those achieved in rAd5 vaccinated subjects (1:32,000 compared to 1:6,800), and CD8+ intracellular cytokine staining was 4.7-fold greater among heterologous prime/boosted subjects (0.41% compared to 0.09%) [59].
3.2.2. Rhabdovirus Vector Vaccines

Rhabdoviruses have recently offered unique vaccine platforms to generate both genus/species specific immunity as well as potential for cross-protective immunity for filoviruses. For example, based on an attenuated recombinant vesicular stomatitis virus (rVSV), the replication-competent virus expresses the glycoprotein of the target filovirus in place of its wild-type membrane glycoprotein. As this virus is primarily an agricultural pathogen, pre-existing immunity interfering with the desired immune response and subsequent protection is unlikely [60]. Several studies have begun to address the safety of the filovirus VSV platforms. Evaluation of this platform in immunocompromised NHPs has suggested that this technology may be safe among similarly immunocompromised humans [61]. Further encouragement for the safety of this live-attenuated vaccine came recently from Mire et al. who showed that EBOV and MARV rVSV showed no signs of neurovirulence associated with VSV [62].

The utility of the VSV-based vaccine for protection against filoviral hemorrhagic fever was highlighted by Geisbert et al. [63]. Using a blended vaccine consisting of equal amounts of three different VSV vectors each carrying the EBOV, SUDV or MARV glycoprotein, they were able to generate 100% protection of NHPs against challenges with EBOV, SUDV, TAFV, and MARV with no observed ill effects from this replication-competent vaccine. Of all vaccinated NHPs, only one showed signs of viremia as assayed by RT-PCR. Each of the vaccinated NHPs also demonstrated elevated antibody responses after vaccination, with titers ranging from 1:32 to 1:100 for all three glycoprotein components of the blended vaccine [63].

In addition to providing such high levels of protection as a prophylactic vaccine strategy, the VSV-based technology has demonstrated post-exposure protection for both EBOV and MARV when administered via intramuscular (i.m.) injection [64]. When MARV-rVSV was administered i.m. 20–30 min post-challenge with MARV, 100% of NHPs survived. In this study viral RNA was observed in the blood on day three post-challenge when assayed by RT-PCR, but active virus was unobservable by traditional plaque assay. Clinical chemistry results demonstrated that these surviving NHPs experienced significant rises in aspartate aminotransferase, gamma-glutamyl transferase, total bilirubin, and blood urea nitrogen indicating that, while protective, the post-exposure treatment did not completely prevent typical pathogenic events associated with MARV infection. Similar experiments demonstrated SUDV-rVSV delivered 20–30 min after challenge offered 100% protection [65]. Post-exposure protection for EBOV-rVSV was less effective at 20–30 min but still afforded 50% protection to eight NHPs [66]. As a post-exposure treatment, EBOV glycoprotein rVSV was used recently 48 h after a suspected human exposure via needlestick in the laboratory. While there is no direct evidence the laboratory worker was indeed exposed, that person survived the experience with no discernible sequelae from the treatment outside of a transient fever occurring 12 h after an injection of $5 \times 10^7$ plaque forming units (PFU) [67].

Also of note for rhabdovirus-based filoviral vaccines was a recent report that generated dual immunity for both EBOV and rabies virus infection. EBOV GP was efficiently expressed from an attenuated vaccine used for wildlife against rabies virus in place of the wild-type rabies envelope glycoprotein, G [68]. This vaccine vector was capable of inducing protective immunity to EBOV infection as well as to rabies virus infection in both live-attenuated format and β-propiolactone inactivated vaccine. Neurovirulence of the recombinant vector was unobserved in suckling mice when
compared to the unaltered vaccine [68]. This versatility offers increased storage options with an inactivated vaccine as well as the opportunity to vaccinate for each disease where they are both endemic.

3.2.3. Venezuelan Equine Encephalitis Virus-Based Replicon Particles (VRP)

Alphavirus particle-based vaccines also provide high levels of protection to NHPs against lethal filovirus challenge. These vaccines for EBOV, SUDV, and MARV are composed of Venezuelan equine encephalitis virus (VEEV)-based replicon particles (VRPs) that express the viral glycoprotein of interest [69]. Replicon particles are replication-defective, single-cycle vectors which cannot spread from cell-to-cell. The VRPs are composed of an attenuated VEEV replicon that contains VEEV non-structural genes and the filovirus glycoprotein. VRPs are generated when the replicon is co-transfected into cells with helper plasmids containing the VEEV structural genes. The resulting single-cycle propagation defective particles are then administered to the appropriate animal model for efficacy testing [69,70]. This technology offers several advantages, including high expression levels of heterologous genes, dendritic cell tropism, induction of robust cellular and antibody immune responses, rapid construction into single and multivalent vaccines, and relative resistance to anti-vector immunity [69,70].

In vivo studies with the MARV VRP offered the first demonstration of a fully protective filovirus vaccine. NHPs exhibited 100% survival after vaccination with 10⁷ focus forming units (FFU) of VRP in three consecutive doses spaced at 28 day intervals prior to challenge with MARV [71]. This protection was offered when the VRPs were constructed to express GP alone or GP + NP; however, the NHPs vaccinated with NP alone all exhibited clinical symptoms of illness and only two out of three survived the challenge. Substantial antibody titers were found in each of the vaccinated NHPs. Additionally, no conspicuous elevations in clinical chemistries were observed in NHPs throughout the experiment. Experiments performed on mice and guinea pigs supported the ability of VRPs expressing GP to mediate complete protection from lethal MARV and EBOV challenge [71]. In mice, adoptive transfer of CD8⁺ cells, but not CD4⁺ cells or passive antibody transfer, from VRP-NP-immunized mice was protective, suggesting this vaccine may be most protective by stimulating the host cell-mediated immune response [72]. Additionally, adoptive transfer of CD8⁺ T-cells after activation via specific EBOV peptides provided mice complete protection indicating a mechanism for VRP-based immunity [73]. Recent studies indicate that a VRP-based vaccine is fully protective in cynomolgus macaques against EBOV, SUDV, and MARV parenteral and aerosol virus challenges (unpublished observations, Olinger).

3.2.4. Paramyxovirus-Based Vaccines

Paramyxovirus-based vectors for vaccination against filoviral threats have recently demonstrated the capacity to protect NHPs from infection and stimulate strong immune responses. Paramyxoviruses have a natural tropism for the respiratory tract and, as filoviruses are both emerging diseases and potential weaponized threats, the idea of targeting vaccines to this area is ideal. Two candidates for this category of vaccines have been investigated to date: human parainfluenza virus 3 (HPIV-3) and Newcastle disease virus (NDV). Of these two systems, the HPIV-3 system has been evaluated in NHP models of EBOV infection. Combinations of EBOV GP alone, EBOV GP + NP, and EBOV GP +
human granulocyte macrophage colony stimulating factor (GM-CSF) were inserted into the genome of HPIV-3. Each of these vaccine vectors was used to vaccinate NHPs both intranasally (i.n.) and intratracheally (i.t.) as initial studies offered complete protection of guinea pigs vaccinated via the respiratory route [74]. At least one NHP in all three vaccine groups receiving $4 \times 10^6$ TCID$_{50}$ (median tissue culture infective dose) of their respective vector displayed clinical signs of illness after challenge during the study. Each group held two NHPs and out of the three groups only one vaccinated animal from the EBOV GP + NP succumbed to the disease. Immune responses from these subjects, prior to challenge, revealed antibody titers ranging from 1:400 to 1:1,600 [75]. By manipulating dose and administration strategies, Bukreyev et al. were able to achieve complete protection of NHPs after two successive doses of $2 \times 10^7$ TCID$_{50}$ given at day zero and again at day 28 with challenge occurring on day 67 [75]. The two-dose strategy produced IgG titers ranging between 1:1,600 and 1:25,600, much higher than the single dose. Each of these experiments highlights the potential of the HPIV-3 platform for EBOV vaccination but the known prevalence of pre-existing immunity to HPIV-3 in humans could hinder the generation of targeted immunity [76]. To address these concerns, Bukreyev et al. compared the immunogenicity of EBOV GP expressing HPIV-3 vector among naïve and pre-immune NHPs [77]. In these experiments EBOV-specific IgG levels were substantially decreased among HPIV-3 pre-immune NHPs; however, this hindrance was overcome when the NHPs were vaccinated with two doses of recombinant vector which was previously shown to offer complete protection against EBOV challenge [77].

In efforts to diversify the paramyxovirus-based vectors and avoid issues surrounding the pre-existing immunity found for HPIV-3, a new vector design based on NDV was established. NDV is an avian paramyxovirus that infects the respiratory tract. This virus has been shown to be highly attenuated in NHPs due to natural host restriction processes [78]. Additionally, this vector system has proven successful as a vaccine platform for severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and influenza H5N1 in NHPs [79]. Although this system has yet to be evaluated in the context of NHP models of EBOV infection and disease, it was recently shown to be immunogenic in NHPs. Single vaccination with NDV expressing EBOV GP produced lower titers than the HPIV-3 platform, demonstrating this vector is less immunogenic; however, in a homologous prime/boost vaccination strategy EBOV-specific mucosal IgA levels reached those similar to the HPIV-3 homologous prime boost vaccination strategy [80]. IgG specific for EBOV did not reach levels comparable to the previous HPIV-3 platform. These reports support the potential use of paramyxoviruses as vaccine candidates, but further examination of immunostimulatory effects and pre-existing immunity will require investigation.

3.2.5. Virus-Like Particles (VLPs)

The VLP technology works by generating non-replicating virus particles that do not contain any filoviral genetic material. Immune responses generated in response to exposure to VLPs are derived from the filoviral protein shell that is the VLP itself. VLPs are constructed through the matrix protein VP40’s ability to drive the budding process. By simple transfection and expression of VP40 into target cells, filamentous structures can be generated [81]. Co-expression of additional filoviral proteins, such as GP and NP, can dramatically enhance and stabilize the production of VLPs from target cells [82].
When traditional target/production cells were swapped out for insect cells and filoviral protein expression was driven from a baculovirus vector, VLPs were generated and found to have filamentous structures resembling wild-type virus. VLPs have demonstrated immunogenicity and the ability to protect NHPs from lethal challenge. The first such study involving NHPs utilized the baculovirus-produced VLPs containing EBOV GP, NP, and VP40 [83]. Five cynomolgus macaques were vaccinated three times at 42-day intervals with 250 µg of VLP with RIBI adjuvant. After the full vaccination schedule, 100% survived a lethal EBOV challenge, and there was a three- to ten-fold increase in EBOV specific antibodies which possessed an 80% plaque reduction at titers between 1:20 and 1:160 [83]. Additionally, these antibodies were shown to have both complement-mediated and antibody-dependent cell-mediated cytotoxic properties [83]. Using this same VLP technology, Swenson et al. were able to show a similar effect for MARV. Three i.m. injections of 1 mg of VLP in 0.1 ml of QS-21 adjuvant spaced 42 days apart offered 100% protection against MARV and RAVV; however, one animal challenged with RAVV did exhibit slight morbidity [84]. All animals had no detectable viremia as determined by plaque assay at days 0, 3, 5, 7, 10, 14, and 21 post-exposure. Additionally, two injections of the VLPs correlated with a peak in homologous antibody titer while three injections correlated to peak heterologous antibody titer [84]. The ability of VLPs to generate protective immunity against filoviral challenge has been demonstrated in guinea pigs as well [85].

3.3. Vaccines Effective in Small Animal Models – Summarized in Table 2

3.3.1. Virus-Like Particles (VLPs) Derived from Baculovirus Vectors

Immunogenic virus-like particles (VLPs) of EBOV and MARV can be easily generated in mammalian systems. EBOV-like particles (VLPs) can be efficiently generated in mammalian cells after expression of VP40 alone, but other filovirus proteins can be co-expressed as well [85–87]. Baculovirus-derived VLPs have also been successfully generated in insect cells and stimulated both cellular and antibody immune responses against hepatitis E virus, human papilloma virus, rotavirus, and simian immunodeficiency virus [88–91]. Several groups have made and tested baculovirus-generated filovirus-VLPs as vaccines in small animal models. Warfield et al. generated Ebola-VLPs (eVLP) and Marburg-VLP (mVLP) containing VP40, NP, and GP. This vaccine had up to 100% survival following a lethal infection in mice (vaccine dose-dependent) [85]. Sun et al. produced an eVLP containing VP40 and GP. This vaccine was also up to 100% effective following a lethal EBOV infection in mice (vaccine dose-dependent) [92,93].

3.3.2. EBOVGPFc Fusion Protein

Many reports document the ability of filoviral GP to act as a potent immunogen, and as such, viral vectors are a popular method of vaccinating through the expression of GP by the host and subsequent immune recognition. However, a recent report sought to utilize GP itself as the vaccination agent. In order to efficiently produce the protein, an expression vector was constructed such that the Fc portion of a human IgG was fused to EBOV-GP [94–96]. This GP-Fc fusion protein induced both cell-mediated and humoral immune responses, and mice vaccinated with ZEBOVGPFc demonstrated 90% protection against a lethal EBOV challenge. [97]. While further studies are required, these results
show that vaccination with EBOVGP-Fc alone is effective against a lethal EBOV infection, and thus fusion proteins could potentially be used as an effective vaccine against filoviruses [97].

3.3.3. Nicotiana Benthamiana-Produced Immune Complex Subunit Vaccine

The use of plants to produce vaccine antigens and antibodies has been demonstrated previously and is attractive for several reasons, including low manufacturing cost, efficient production, minimal risk of contamination with human pathogens or toxins, and the fact that plants have similar secretory pathways and endosomal systems as mammalian cells [98–101]. Recently, a bean yellow dwarf virus (BeYDV)-derived replicon system was developed and shown to efficiently produce antibodies against EBOV in *Nicotiana benthamiana* leaves [100]. Poolcharoen *et al.* used this system to develop and fuse EBOV-GP1 to the C-terminus of an IgG heavy chain [102]. These EBOV immune complexes (EIC) were then used as a vaccine to immunize mice. Serum antibody response tests showed that this EIC was highly immunogenic in mice and produced antibody levels similar to mice protected from a lethal EBOV challenge [102]. While antibody titers alone do not fully correlate with protection from lethal challenge, there is potential for further development of this vaccine.

3.3.4. MCMV/EBOV-NPCTL

A replicating vaccine that could spread through the target population after initial inoculation would be an attractive, alternative approach to filovirus development. This approach could provide high coverage with minimal initial vaccinations. A CMV-based vaccine would allow for this type of
spread [103]. CMV, a member of the family Betaherpesvirinae, induces a high “effector” memory T-cell (TEM) response before establishing a low-level persistent infection [104–106]. This high immunogenicity makes CMV a good potential vaccine vector, and the CMV vector has been previously shown to be effective as a vaccine for SIV in rhesus macaques [104,107]. Tsuda et al. constructed a mouse CMV vector expressing a CD8+ T cell epitope from the nucleoprotein (NP) of EBOV (MCMV/EBOV-NPCTL). This vaccine induced high levels of EBOV-specific CD8+ T cells, and subsequently, protected 100% of mice against a lethal EBOV challenge. This shows a proof-of-concept for CMV as a potential vaccine vector for EBOV [103].

3.3.5. HPIV3/ΔF-HN/EboGP

As discussed previously, paramyxovirus-based vectors have demonstrated the capacity to induce strong immune responses and protect animals from infection. As such, a chimeric HPIV3 was developed where all the HPIV3 surface markers/receptors were deleted and replaced with EBOV-GP [108]. This chimeric virus can be amplified and recovered easily. Additionally, this chimeric virus has 2-fold greater incorporation of EBOV-GP into the virion due to the lack of competition with HPIV3 surface proteins [108]. Testing in guinea pigs showed that HPIV3/ΔF-HN/EboGP is highly attenuated, as compared to both HPIV3 and HPIV3/EboGP, and immunogenic, as 67% developed neutralizing antibodies against EBOV. Finally, a 4 × 10^6 PFU i.n. inoculation of HPIV3/ΔF-HN/EboGP was able to protect 100% of guinea pigs against a lethal EBOV challenge [108].

4. Post-Exposure Treatments

4.1. Post-Exposure Treatments in Human Clinical Trials – Summarized in Table 3

4.1.1. rNAPc2

Severe coagulation disorders are one of the most prominent features of filoviral infection. In the event of a breach in vascular integrity a strict balance of pro- and anti-coagulant host factors must be maintained to successfully clot the breach and to prevent too much or too little clot formation. In the instance of filovirus infection, sustained microvascular injury in effected organs results in host coagulation inhibitor depletion which results in disseminated intravascular coagulation (DIC). In DIC, tissue factor (TF), a clotting factor normally present on cells not exposed to blood, complexes with circulating factor VII leading to clot formation and fibrin deposition through the extrinsic pathway [109,110]. As numerous studies have demonstrated a clear link with DIC and resultant organ failure, Geisbert et al, sought to eliminate potential TF pathogenesis during filovirus infection by using recombinant nematode anticoagulant protein c2 (rNAPc2) [111]. They demonstrated that rNAPc2, an inhibitor of the TF pathway, provided partial post-exposure protection to rhesus macaques during filovirus infection [111]. Previous studies with rNAPc2 have already gone through phase II trials in orthopedic surgery [112] and coronary revascularization [113]. Geisbert et al. showed a 33% survival rate, in addition to a 3.4-day increase in mean time-to-death, for EBOV-infected rhesus macaques and a 17% survival rate, with a 1.7-day increase in mean time-to-death, in MARV-infected rhesus macaques, when treated with rNAPc2 post-exposure [111,114]. In a normally 100% lethal model of
filovirus infection, rNAPc2 demonstrated a clear benefit to survival as an increase in the mean time-to-death was observed. rNAPc2 has completed phase II clinical trials with a good safety record.

Table 3. Post-Exposure Treatments in Human Clinical Trials or Effective in Non-human Primates. Comparison of current drug candidates at the highest level of development, either in human clinical trials or those that have shown promise in NHPs. Also listed are the afforded levels of protection in NHPs, the type of drug used to induce immunity and the dosing paradigm used to achieve the listed results.

| Treatment | Type | Mechanism | Species Tested | Efficacy | Strategy |
|-----------|------|-----------|----------------|----------|----------|
| rNAPc2    | Recombinant protein | Blocks TF:FVIIa mediated activation of factor X | Rhesus macaque | 33% (EBOV) 17% (MARV) | Daily s.c. injection of 30 µg/kg |
| RNA Interference | PMOs | Targets viral mRNA to block transcription | Rhesus macaque | Drug dependent—may be up to 100% immediately post-exposure | Daily s.c./i.p. or i.v. injections of 40 mg/kg |
| rhAPC     | Recombinant protein | Anti-thrombotic: cleaves and inhibits coagulation cofactors FVIIIa and FVa | Rhesus macaque | 20% (EBOV) | Daily s.c. injection of 30 µg/kg |

4.1.2. Phosphorodiamidate Morpholino Oligomers

Phosphorodiamidate morpholino oligomers (PMOs) exert their anti-translation effects through steric hindrance of the translation machinery. This steric hindrance is possible due to a morpholino group, similar to a ribose base in RNA, and a methylene phosphorodiamidate linking moiety that physically bind to mRNA and prevent the translation machinery from accessing the mRNA [115]. Once the antisense PMOs bind to their target mRNA, they are highly stable and highly soluble which would allow high levels of translation inhibition and predictably low levels of potential cytotoxicity [115–118]. PMOs have previously demonstrated effective antiviral activity against coronaviruses and flaviviruses [119,120]. Swenson et al. initially utilized PMOs targeting EBOV VP24 and EBOV VP35 to highly protect mice and guinea pigs against a lethal challenge with EBOV and MARV [121,122]. Subsequently, AVI-6002 (a combination of PMOs against both EBOV VP24 and VP35) and AVI-6003 (a combination of PMOs against both MARV VP24 and NP) were developed and tested in a NHP post-exposure scenario. These PMOs, delivered 30–60 min post-exposure, protected >60% of rhesus macaques against lethal EBOV infection and 100% of cynomolgus macaques against MARV infection [123]. Both the ease of controlled manufacture and their efficacy in NHP models to combat filovirus infection, PMOs represent a viable therapeutic strategy [123]. Currently, AVI-6002 and AVI-6003 are in phase I clinical trials.
4.2. Post-Exposure Treatments Effective in NHPs – Summarized in Table 3

4.2.1. Recombinant Human Activated Protein C

Ebola virus disease (EVD) and severe sepsis (or septic shock) share many clinical features including fever, hypotension, increased production of tissue factor, elevated levels of nitric oxide, and elevated levels of D-dimers [124–126]. In addition, the most prominent and consistent finding in severe sepsis is severe protein C deficiency [127,128]. It was shown that treatment of patients with severe sepsis with recombinant human activated protein C (rhAPC) resulted in improved survival [129]. Later experiments in NHPs demonstrated that EBOV infection results in rapid reduction of circulating protein C levels [111,130]. Therefore, it was tested if treatment with rhAPC could protect against lethal EBOV infection in rhesus macaques. Fourteen rhesus macaques were infected with a lethal dose of EBOV; eleven were then treated with IV rhAPC 30–60 min after challenge, continuing for 7 days. All control animals died on day 8 post-exposure; however, 2 of the 11 rhAPC-treated animals survived (~20% survival). Additionally, the mean time-to-death for rhAPC-treated animals was 12.6 days, which is significant compared to the 8.3 days observed in placebo and historical controls [125]. This product was pulled as a single post-exposure treatment, but given that this intervention is not directly targeting the virus, there may be additional merit in assessing this product in conjunction with a direct antiviral.

4.2.2. RNA Interference and Stable Nucleic Acid Lipid Particles

RNA interference (RNAi) represents a powerful, naturally occurring biological strategy for inhibiting gene expression. RNAi interferes with the translation of mRNA to protein products by either sterically blocking mRNA or by triggering RNase H-mediated cleavage of the DNA/RNA duplex, resulting in inhibition of gene expression [122]. For many years RNAi as demonstrated clear efficacy in preventing viral replication in vitro against a number of viruses, including coxsackieviruses, hepatitis B virus (HBV), hepatitis C virus (HCV), herpesviruses, human immunodeficiency virus 1 (HIV), human papillomavirus, RSV, influenza A virus, lymphocytic choriomeningitis virus, polioviruses, and SARS-CoV [131–134]. Fowler et al. demonstrated that small-interfering RNA (siRNA) downregulation of various MARV mRNA transcripts was able to significantly decrease viral protein production and subsequent viral release in cell culture [135]. Unfortunately, efficient delivery vehicles providing effective drug targeting and stability have hindered the application of RNAi in the clinical setting. However, recent developments in the field of nanotechnology have made nanoparticles the solution to increasing pharmacokinetic profiles for RNAi therapies [136].

Additionally, Tekmira, Inc. developed proprietary lipid encapsulation as a means of improving the pharmacology of siRNA targeting the Ebola RNA polymerase L protein, as demonstrated by Geisbert et al. [137,138]. To efficiently deliver the siRNA to target cells, a mixture of lipids forming a bilayered liposome, or stable nucleic acid-lipid particles (SNALP), was designed. The SNALP ensures cell entry by preferential fusing with the endosomal membrane upon exposure to the decreasing pH of the endosome. The SNALPs were further modified by conjugation with polyethylene glycol (PEG) ensuring stability and efficient delivery of the siRNA payload by neutralizing surface charges and presenting a hydrophilic exterior. This encapsulation was initially demonstrated to significantly
increase the stability, half-life, and effectiveness of siRNA directed against HBV [139]. The SNALP-encapsulation of siRNA targeting the EBOV L protein was initially shown to completely protect guinea pigs when administered shortly after a lethal EBOV challenge [137]. This treatment was then assessed for efficacy in rhesus macaques. SNALP-encapsulated siRNAs targeting EBOV L polymerase, VP24, and VP35 were given to rhesus monkeys either four or seven times following a lethal challenge of EBOV. Two of the three monkeys given four doses survived lethal infection, while all four monkeys given seven doses survived infection [138]. The enhanced survivorship among the SNALP-treated group highlights the efficacy of this potential therapeutic. Additionally, there was little to no evidence of side effects associated with the treatment group, aside from mildly altered liver enzyme levels (which could have been an artifact separate from the challenge course) [138].

4.3. Post-Exposure Treatments Effective in Small Animal Models – Summarized in Table 4

4.3.1. Mannose-Binding Lectin

Innate immunity is often the first line of defense against invading pathogens. One mechanism by which innate immunity functions relies on the identification of pathogen-associated molecular patterns (PAMPs). PAMPs consist of unique carbohydrate moieties on the external surfaces of foreign microbes, such as hexose and mannose, which are not expressed on the surfaces of the host cells. These PAMPs are then recognized by host proteins such as mannose-binding lectins (MBL), which recognize these high hexose and mannose contents [140]. Filoviruses have large amounts of mannose comprising their glycoproteins and thus are a target of MBL [141]. Upon exposure, host MBL targets filoviruses for complement-dependent virus neutralization through the lectin pathway of the complement cascade [142]. When administered in supraphysiological doses before or after lethal challenge with EBOV, recombinant MBL treatment protected 40% of mice [140]. These studies showed that MBL may be a potential post-exposure prophylactic.

Table 4. Post-Exposure Treatments Effective in Small Animal Models. Comparison of current treatment candidates at the small animal model level of development, specifically mouse models. Also listed are the afforded levels of protection, the type of drug used to induce immunity and the dosing paradigm used to achieve the listed results.

| Drug                              | Type                  | Mechanism                                                                 | Species Tested | Efficacy                  | Strategy                                                                 |
|-----------------------------------|-----------------------|---------------------------------------------------------------------------|---------------|---------------------------|--------------------------------------------------------------------------|
| Mannose-binding Lectin            | C-type Lectin         | Binds to virus and mediates complement-dependent virus neutralization     | Mice          | 40% (EBOV)                | 350 µg i.p. injection, twice daily for 10 days                            |
| Small-molecule inhibitors         | Compound dependent    | Compound dependent                                                        | Mice          | Compound and dose dependent, ranging from 40%–100% (EBOV and MARV)    | Single i.p. injection of 2–5 mg/kg between 1–3 days post-exposure         |
| Hexamminecobalt (III) Chloride    | Metal ion based drug  | Inhibits viral replication                                                | Mice          | 20% (EBOV)                | Daily i.p. injections of 2–8 mg/kg                                        |
4.3.2. Small-Molecule Inhibitors

High-throughput screening (HTS) is a significant tool for novel drug discovery. HTS involves screening libraries consisting of thousands to hundreds of thousands of unique molecules against specific targets. Available libraries used in HTS have included natural compounds [143,144], peptides [145], drugs [146], and synthetic compounds [144,147]. Recently, compound FGI-103 was identified during a screen with an EBOV-GFP pseudotyped virus and has shown strong antiviral activity in vitro against high doses of EBOV and MARV. FGI-103 was subsequently shown to protect mice against lethal challenges of both EBOV and MARV [148]. Additionally, compound FGI-106 was initially identified in a similar manner and was shown to exhibit strong antiviral activity in vitro against EBOV, Rift Valley fever virus (RVFV), all four types of dengue virus (DENV), HCV, and HIV-1. FGI-106 also protected mice against a lethal challenge of EBOV when given post-exposure [149]. Taken together, this suggests that FGI-106 probably acts on a conserved pathway common to these four viruses, and potentially makes for a very intriguing antiviral.

A second screen was done using a collection of 1,990 small molecule compounds obtained from the NCI and the EBOV-GFP pseudotyped virus [150]. As a result, NSC 62914, a reactive oxygen species scavenger, was identified and shown to have high antiviral activity against EBOV, MARV, Lassa virus, RVFV, and VEEV. In vivo studies demonstrated that this compound protected mice against a lethal challenge of EBOV and MARV when given either pre- or post-exposure [151].

4.3.3. Hexamminecobalt (III) Chloride

Metal ion-based therapeutics are a new potential class of drugs because they differ from carbon-based compounds due to the charged central ion which determines the molecular geometry of the compound. Through these unique molecular geometries, specific compounds can be isolated that inhibit biological processes, and are unlike traditional carbon-based compounds because of their unique geometry. This difference allows these compounds to form octahedral and square planar molecular geometries. Hexamminecobalt (III) chloride (Cohex) is a complex of a cobalt (III) ion surrounded by six ammonia ligands in a full octahedral coordination. Cohex was initially reported to have antiviral activity against adenovirus and Sindbis virus, and was subsequently thought to have potential broad-spectrum antiviral activities [152]. Cohex was shown to be well-tolerated in mice with no apparent toxicity. Mice were treated with Cohex daily and infected with a lethal dose of EBOV. Cohex-treated mice had a significant increase in mean time-to-death, and the highest concentration treatment group had a 20% survival rate [152]. This suggests that Cohex has the potential to be an effective treatment against EBOV infection.

4.4. Compounds Effective In Vitro

4.4.1. Niemann-Pick C1

Niemann-Pick C1 (NPC1), a cholesterol transporter found in endosomes and lysosomes, was recently identified as being required for EBOV replication during a gene trap screen in HAP1 cells using a replication-competent VSV bearing the EBOV glycoprotein (rVSV-GP-EBOV). In these
Viruses 2012, 4

experiments, cells with non-functional NPC1 demonstrated decreased infectivity by rVSV-GP-EBOV; however, expression of a functional NPC1 rescued the normal infectivity of these viruses [20]. NPC1 is known to affect calcium homeostasis as well as endosomal and lysosomal fission and fusion [153–155]. It has also been shown to be involved in HIV-1 release [156]. Loss of NPC1 causes a neurological disorder called Niemann–Pick disease, which is characterized by cholesterol accumulation in lysosomes [153]. While heterozygous NPC1 knockout mice \((NPC1^{+/−})\) do not show evidence of Niemann-Pick disease, most \(NPC1^{+/−}\) knockout mice were protected against a lethal challenge of mouse adapted EBOV (80% survival) and MARV (100% survival) [20]. Additionally, small molecules, such as U18666A, have been identified that interfere with NPC1 and cause a cellular phenotype similar to \(NPC1\) deficiency [157]. As such, U18666A was subsequently shown to block infection of EBOV \(\textit{in vitro}\) [21].

4.4.2. HSP-90 Inhibitors

Heat-shock protein 90 (Hsp90) is a molecular chaperone that aids in the folding, trafficking, and proteolytic processing of many proteins [158,159]. As a result of their many functionalities, Hsp90 inhibitors have been designed to combat diseases such as cancer, and there are currently several drugs now in Phase I and II clinical trials [160,161] Additionally, Hsp90 has shown to be important for replication of negative-strand viruses, as well as HCV, HBV, and polio [162–165]. The effects of several natural and synthetic Hsp90 inhibitors on EBOV replication were tested \(\textit{in vitro}\). Results of this study demonstrated that three Hsp90 inhibitors significantly inhibited the replication of EBOV in Vero cells and primary human monocytes, suggesting their use as a potential therapeutic [158].

4.4.3. \(\Delta\)-Peptide Immunoadhesins

Ebolaviruses express two secreted glycoproteins, soluble GP (sGP) and small soluble GP (ssGP) [166]. sGP has been associated with stabilization of the endothelial barrier function and reduction of endothelial barrier permeability by opposing the effects of TNF-\(\alpha\). These effects are in direct opposition to the observed roles for GP, which has been associated with endothelial cell destruction [167]. ssGP has yet to have a clear role during infection [166]. Each of the GP forms contains identical N-termini but differ in the structure of their C-termini. During the differentiation process of the C-termini, the homodimer sGP is cleaved by furin to yield the mature sGP and a \(\Delta\)-peptide which is retained in cells longer as compared to sGP. When these \(\Delta\)-peptides from EBOV, SUDV, and TAFV were fused with Fc tags and transfected into cells before infection, they were capable of inhibiting both EBOV and MARV infection in a dose dependent fashion [166]. These observations indicated that \(\Delta\)-peptides might play an important role in filovirus pathogenesis, and could be exploited as a novel anti-filoviral therapeutic [166].

4.4.4. C-Peptides

While many events in filovirus entry remain undiscovered, a fusion mechanism similar to HIV and SARS-CoV is thought to occur such that a conformational rearrangement of glycoproteins on the viral surface results in viral fusion with the cellular membrane. Inhibitors of viral fusion have been
developed for HIV-1 and SARS-CoV. These inhibitors prevent the C-terminal heptad repeat in the envelope protein from interacting with the cellular membrane proteins by directly competing and blocking its interaction with the N-terminal heptad repeat, which normally would result in the formation of the six-helix bundle required for membrane fusion. C-peptides, which are inhibitors of viral envelope fusion, have had limited success against filoviruses in the past, most likely due to the suggestive evidence that filovirus fusion occurs far along in the endosomal maturation process [168–172]. However, when these C-peptides were conjugated with an argenine-rich segment of HIV-1’s TAT protein (a protein known for its endosomal localization) the conjugated C-peptide exhibited marked antiviral effects, up to 99% inhibition of EBOV and MARV in vitro [172–174]. Unfortunately, the concentrations used to generate this inhibition in vitro were not possible in the clinical setting, but this report indicates that future C-peptide research may result in filovirus entry prevention for future therapeutics.

4.4.5. Alkylated Porphyrins

A recent report that screened 2,200 molecules demonstrated that chlorophyllide was able to decrease the section of HBV DNA in a HBV antiviral assay. These results were obtained at compound concentrations which exhibited no cytotoxic effects. This molecule is an alkylated porphyrin containing copper and as such this compound is carries a charge at neutral pHs [175]. During these screens, the chlorin e6 compound, a metal-free chlorophyllide-like molecule, was found to be the most potent and was subsequently tested against other viruses, including MARV. During testing, the chlorine e6 compound showed significant antiviral activity in vitro against MARV. This compound also inhibited Junin virus, DENV, HCV, and HIV-1 [175].

4.4.6. Benzodiazepine Small Molecule Compounds

Another recent study that examined a library of 52,500 compounds yielded 57 candidates capable of generating ≥90% inhibition of a HIV-1/EBOV-GP pseudotyped virus, while not interfering with the HIV-1/VSV-G control virus. From these candidates, compound 7, a benzodiazepine derivative, showed an ability to inhibit both EBOV and MARV to a similar degree in vitro [176]. Results from these experiments suggested that compound 7 acts at an early stage of viral entry, preventing infection by an unknown mechanism [176].

4.4.7. LJ001

LJ001, an aryl methyldiene rhodanine derivative, was identified during a high-throughput screening of inhibitors for Nipah virus entry in the context of a VSV-pseudotyped vector [177]. This compound was subsequently shown to inhibit a variety of enveloped viruses, including MARV, EBOV, Nipah, RVFV, HIV-1, HCV, WNV, etc. [177]. However, it did not inhibit nonenveloped viruses such as adenovirus and reovirus. Further testing demonstrated that LJ001 binds to the viral membrane and prevents virus-cell fusion. While initial testing in mice did not show antiviral efficacy, further development of this compound to improve pharmacokinetics and potency is distinctly possible [177].
5. Conclusions

Development of medical countermeasures for EBOV and MARV remain a high priority and substantial progress has been made over the past decade. We have moved from the inability to protect from infection in various animal models of disease to a realm of medical countermeasures that protect prophylactically and more recently successful treatments that can be employed following known exposure to the viruses. Initial efforts, focused on preventing the disease with vaccination strategies, ranged from subunit vaccines to VLPs, vectored systems, DNA vaccines, and live-attenuated virus systems that express the EBOV or MARV glycoproteins. To that aim, vaccine efficacy has been achieved by multiple vaccines against parenteral and aerosol routes of exposure. With the success of these new vaccine platforms, the attention of the past 5 years has focused on the ability to treat infected patients. In the animal models, success has been demonstrated with traditional small molecules and antibodies directed against the virus or critical host proteins or pathways associated with pathogenesis. The ability to utilize various RNA silencing technologies has been a focus for therapeutics that could be beneficial for filovirus infection, other infectious diseases and cancer therapy. Despite these successes, there is much work to do to adequately prepare for this infectious threat. The ability to provide a beneficial therapeutic impact at a point when patients experience clinical symptoms and seek relief from caregivers remains a hurdle for the medical countermeasure development. Moreover, the quality of life of patients following infection and treatment may require additional development efforts or the combination of multiple therapeutic approaches. As seen in outbreaks, the clinical sequelae observed in patients that survive infection are severe and life changing. These observations emphasize the need for medical countermeasures that not only provide survival but also decrease morbidity and long-term pathological outcomes following infection. Lastly, the funding resources fortitude and the ability to navigate regulatory pathways will be essential to reaching either emergency use authorization (EUA) status or licensed drug status for therapeutics and vaccines. However, the field remains optimistic that medical countermeasure solutions for human use are possible.

Acknowledgments

BMF and JCT are National Research Council (NRC) postdoctoral fellows. BMF is also funded by JSTO-NRC CBD postdoctoral funds from DTRA. ANH is partially supported by Joint Project Management Office for Transformational Medical Technologies agreement TMTI0017_09_RD_T from the Department of Defense Chemical and Biological Defense Program. GGO is supported by the DTRA grant CBCALL12-THRFDFA1-2-0135.

Disclaimer: Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Conflict of Interest

The authors declare no conflict of interest.
1. Kuhn, J.H.; Becker, S.; Ebihara, H.; Geisbert, T.W.; Johnson, K.M.; Kawaoka, Y.; Lipkin, W.I.; Negredo, A.I.; Netesov, S.V.; Nichol, S.T.; et al. Proposal for a revised taxonomy of the family filoviridae: Classification, names of taxa and viruses, and virus abbreviations. *Arch. Virol.* **2010**, *155*, 2083–2103.

2. Kuhn, J.H.; Becker, S.; Ebihara, H.; Geisbert, T.W.; Jahrling, P.; Kawaoka, Y.; Netesov, S.V.; Nichol, S.T.; Peters, C.J.; Volchkov, V.E.; et al. Family Filoviridae. In *Virus Taxonomy-Ninth Report of the International Committee on Taxonomy of Viruses*; King, A.M.Q., Adams, M.J., Carstens, E.B., Lefkowitz, E.J., Eds.; Elsevier/Academic Press: London, UK, 2011; pp. 665–671.

3. Martini, G.A.; Knauff, H.G.; Schmidt, H.A.; Mayer, G.; Baltzer, G. A hitherto unknown infectious disease contracted from monkeys. "Marburg-virus" disease. *Ger. Med. Mon.* **1968**, *13*, 457–470.

4. Kiley, M.P.; Bowen, E.T.; Eddy, G.A.; Isaacson, M.; Johnson, K.M.; McCormick, J.B.; Murphy, F.A.; Pattyn, S.R.; Peters, D.; Prozesky, O.W.; et al. Filoviridae: A taxonomic home for marburg and ebola viruses? *Intervirology* **1982**, *18*, 24–32.

5. Kuhn, J.H. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. *Arch. Virol. Suppl.* **2008**, *20*, 13–360.

6. Gene, O.G.; Julia, B.E.; Vanessa, M.R.; Victoria, W.J.; Thomas, G.W.; Lisa, H.E. Drug targets in infections with ebola and marburg viruses. *Infect. Disord. Drug Targets* **2009**, *9*, 191–200.

7. Gonzalez, J.P.; Pourrut, X.; Leroy, E. Ebolavirus and other filoviruses. *Curr. Top. Microbiol. Immunol.* **2007**, *315*, 363–387.

8. Leroy, E.M.; Epelboin, A.; Mondonge, V.; Pourrut, X.; Gonzalez, J.P.; Muyembe-Tamfum, J.J.; Formenty, P. Human ebola outbreak resulting from direct exposure to fruit bats in luebo, democratic republic of congo, 2007. *Vector Borne Zoonotic Dis.* **2009**, *9*, 723–728.

9. Pourrut, X.; Delicat, A.; Rollin, P.E.; Ksiazek, T.G.; Gonzalez, J.P.; Leroy, E.M. Spatial and temporal patterns of zaire ebolavirus antibody prevalence in the possible reservoir bat species. *J. Infect. Dis.* **2007**, *196*, S176–S183.

10. Pourrut, X.; Souris, M.; Towner, J.S.; Rollin, P.E.; Nichol, S.T.; Gonzalez, J.P.; Leroy, E. Large serological survey showing cocirculation of ebola and marburg viruses in gabonese bat populations, and a high seroprevalence of both viruses in rousettus aegyptiacus. *BMC Infect. Dis.* **2009**, *9*, doi:10.1186/1471-2334-9-159.

11. Towner, J.S.; Pourrut, X.; Albarino, C.G.; Nkogue, C.N.; Bird, B.H.; Grard, G.; Ksiazek, T.G.; Gonzalez, J.P.; Nichol, S.T.; Leroy, E.M. Marburg virus infection detected in a common african bat. *PLoS One* **2007**, *2*, e764.

12. Barrette, R.W.; Metwally, S.A.; Rowland, J.M.; Xu, L.; Zaki, S.R.; Nichol, S.T.; Rollin, P.E.; Towner, J.S.; Shihe, W.J.; Batten, B.; et al. Discovery of swine as a host for the reston ebolavirus. *Science* **2009**, *325*, 204–206.

13. Geisbert, T.W.; Jahrling, P.B. Differentiation of filoviruses by electron microscopy. *Virus Res.* **1995**, *39*, 129–150.

14. Regnery, R.L.; Johnson, K.M.; Kiley, M.P. Virion nucleic acid of ebola virus. *J. Virol.* **1980**, *36*, 465–469.
15. Sanchez, A.; Geisbert, T.W.; Feldmann, H. Filoviridae: Marburg and Ebola Viruses. In Fields Virology; Knipe, D.M., Howley, P.M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007; Volume 1, pp. 1409–1448.

16. Richardson, J.S.; Dekker, J.D.; Croyle, M.A.; Kobinger, G.P. Recent advances in ebolavirus vaccine development. Hum. Vaccin 2010, 6, 439–449.

17. Bradfute, S.B.; Dye, J.M., Jr.; Bavari, S. Filovirus vaccines. Hum. Vaccin 2011, 7, 701–711.

18. Volchkov, V.E.; Feldmann, H.; Volchkova, V.A.; Klenk, H.D. Processing of the ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. USA 1998, 95, 5762–5767.

19. Alvarez, C.P.; Lasala, F.; Carrillo, J.; Muniz, O.; Corbi, A.L.; Delgado, R. C-type lectins dc-sign and l-sign mediate cellular entry by ebola virus in cis and in trans. J. Virol. 2002, 76, 6841–6844.

20. Carette, J.E.; Raaben, M.; Wong, A.C.; Herbert, A.S.; Obernosterer, G.; Mullherkar, N.; Kuehne, A.I.; Kranzusch, P.J.; Griffin, A.M.; Ruthel, G.; et al. Ebola virus entry requires the cholesterol transporter niemann-pick c1. Nature 2011, 477, 340–343.

21. Cote, M.; Misasi, J.; Ren, T.; Bruchez, A.; Lee, K.; Filone, C.M.; Hensley, L.; Li, Q.; Ory, D.; Chandran, K.; et al. Small molecule inhibitors reveal niemann-pick c1 is essential for ebola virus infection. Nature 2011, 477, 344–348.

22. Kondratowicz, A.S.; Lennemann, N.J.; Sinn, P.L.; Davey, R.A.; Hunt, C.L.; Moller-Tank, S.; Meyerholz, D.K.; Rennert, P.; Mullins, R.F.; Brindley, M.; et al. T-cell immunoglobulin and mucin domain 1 (tim-1) is a receptor for zaire ebolavirus and lake victoria marburgvirus. Proc. Natl. Acad. Sci. USA 2011, 108, 8426–8431.

23. Genton, C.; Cristescu, R.; Gatti, S.; Leverero, F.; Bigot, E.; Caillaud, D.; Pierre, J.S.; Menard, N. Recovery potential of a western lowland gorilla population following a major ebola outbreak: Results from a ten year study. PLoS One 2012, 7, e37106.

24. Bradfute, S.B.; Bavari, S. Correlates of immunity to filovirus infection. Viruses 2011, 3, 982–1000.

25. Roddy, P.; Colebunders, R.; Jeffs, B.; Palma, P.P.; van Herp, M.; Borchert, M. Filovirus hemorrhagic fever outbreak case management: A review of current and future treatment options. J. Infect. Dis. 2011, 204, S791–S795.

26. Jeffs, B.; Roddy, P.; Weatherill, D.; de la Rosa, O.; Dorion, C.; Iscla, M.; Grovas, I.; Palma, P.P.; Villa, L.; Bernal, O.; et al. The medecins sans frontieres intervention in the marburg hemorrhagic fever epidemic, uige, angola, 2005. I. Lessons learned in the hospital. J. Infect. Dis. 2007, 196, S154–S161.

27. Singhi, S.; Kissoon, N.; Bansal, A. Dengue and dengue hemorrhagic fever: Management issues in an intensive care unit. J. Pediatr. (Rio J) 2007, 83, S22–S35.

28. Kortepeter, M.G.; Lawler, J.V.; Honko, A.; Bray, M.; Johnson, J.C.; Purcell, B.K.; Olinger, G.G.; Rivard, R.; Hepburn, M.J.; Hensley, L.E. Real-time monitoring of cardiovascular function in rhesus macaques infected with zaire ebolavirus. J. Infect. Dis. 2011, 204, S1000–S1010.

29. Stroher, U.; Feldmann, H. Progress towards the treatment of ebola haemorrhagic fever. Expert Opin. Investig. Drugs 2006, 15, 1523–1535.

30. Fernandez, P.; Trenholme, A.; Abarca, K.; Griffin, M.P.; Hultquist, M.; Harris, B.; Losonsky, G.A. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory
syncytial virus (rsv) prophylaxis with motavizumab and palivizumab administered in the same season. *BMC Pediatr.* **2010**, *10*, doi:10.1186/1471-2431-10-38.

31. Geevarghese, B.; Simoes, E.A. Antibodies for prevention and treatment of respiratory syncytial virus infections in children. *Antivir. Ther.* **2012**, *17*, 201–211.

32. Feldmann, H.; Jones, S.; Klenk, H.D.; Schnittler, H.J. Ebola virus: From discovery to vaccine. *Nat. Rev. Immunol.* **2003**, *3*, 677–685.

33. Mupapa, K.; Massamba, M.; Kibadi, K.; Kuvula, K.; Bwaka, A.; Kipasa, M.; Colebunders, R.; Muyembe-Tamfum, J.J. Treatment of ebola hemorrhagic fever with blood transfusions from convalescent patients. International scientific and technical committee. *J. Infect. Dis.* **1999**, *179*, S18–S23.

34. Slenczka, W.G. The marburg virus outbreak of 1967 and subsequent episodes. *Curr. Top. Microbiol. Immunol.* **1999**, *235*, 49–75.

35. Stille, W.; Bohle, E.; Helm, E.; van Rey, W.; Siede, W. An infectious disease transmitted by cercopithecus aethiops. ("green monkey disease"). *Ger. Med. Mon.* **1968**, *13*, 470–478.

36. Jahrling, P.B.; Geisbert, T.W.; Geisbert, J.B.; Swearengen, J.R.; Bray, M.; Jaax, N.K.; Huggins, J.W.; LeDuc, J.W.; Peters, C.J. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental ebola virus infections. *J. Infect. Dis.* **1999**, *179*, S224–S234.

37. Oswald, W.B.; Geisbert, T.W.; Davis, K.J.; Geisbert, J.B.; Sullivan, N.J.; Jahrling, P.B.; Parren, P.W.; Burton, D.R. Neutralizing antibody fails to impact the course of ebola virus infection in monkeys. *PLoS Pathog.* **2007**, *3*, e9.

38. Takada, A.; Ebihara, H.; Jones, S.; Feldmann, H.; Kawaoka, Y. Protective efficacy of neutralizing antibodies against ebola virus infection. *Vaccine* **2007**, *25*, 993–999.

39. Nakayama, E.; Tomabechi, D.; Matsuno, K.; Kishida, N.; Yoshida, R.; Feldmann, H.; Takada, A. Antibody-dependent enhancement of marburg virus infection. *J. Infect. Dis.* **2011**, *204*, S978–S985.

40. Takada, A.; Ebihara, H.; Feldmann, H.; Geisbert, T.W.; Kawaoka, Y. Epitopes required for antibody-dependent enhancement of ebola virus infection. *J. Virol.* **2003**, *77*, 7539–7544.

41. Parren, P.W.; Geisbert, T.W.; Rensink, I.; Rodriguez, L.L.; Khan, A.S.; Peters, C.J.; Burton, D.R. Recombinant human monoclonal antibodies to ebola virus. *J. Infect. Dis.* **1999**, *179*, S235–S239.

42. Maruyama, T.; Parren, P.W.; Sanchez, A.; Rensink, I.; Rodriguez, L.L.; Khan, A.S.; Peters, C.J.; Burton, D.R. Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. *J. Virol.* **2002**, *76*, 6408–6412.

43. Wilson, J.A.; Hevey, M.; Bakken, R.; Guest, S.; Bray, M.; Schmaljohn, A.L.; Hart, M.K. Epitopes involved in antibody-mediated protection from ebola virus. *Science* **2000**, *287*, 1664–1666.

44. Dye, J.M.; Herbert, A.S.; Kuehne, A.I.; Barth, J.F.; Muhammad, M.A.; Zak, S.E.; Ortiz, R.A.; Prugar, L.I.; Pratt, W.D. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 5034–5039.
46. Marzi, A.; Yoshida, R.; Miyamoto, H.; Ishijima, M.; Suzuki, Y.; Higuchi, M.; Matsuyama, Y.; Igarashi, M.; Nakayama, E.; Kuroda, M.; et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of ebola hemorrhagic fever. *PLoS One* 2012, 7, e36192.

47. Qiu, X.; Audet, J.; Wong, G.; Pillet, S.; Bello, A.; Cabral, T.; Strong, J.E.; Plummer, F.; Corbett, C.R.; Alimonti, J.B.; et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. *Sci. Transl. Med.* 2012, 4, 138–181.

48. Zeitlin, L.; Pettitt, J.; Scully, C.; Bohorova, N.; Kim, D.; Pauly, M.; Hiatt, A.; Ngo, L.; Steinkellner, H.; Whaley, K.J.; et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an ebola virus immunoprotectant. *Proc. Natl. Acad. Sci. USA* 2011, 108, 20690–20694.

49. Qiu, X.; Alimonti, J.B.; Melito, P.L.; Fernando, L.; Stroher, U.; Jones, S.M. Characterization of zaire ebolavirus glycoprotein-specific monoclonal antibodies. *Clin. Immunol.* 2011, 141, 218–227.

50. Lee, J.E.; Saphire, E.O. Neutralizing ebolavirus: Structural insights into the envelope glycoprotein and antibodies targeted against it. *Curr. Opin. Struct. Biol.* 2009, 19, 408–417.

51. Martin, J.E.; Sullivan, N.J.; Enama, M.E.; Gordon, I.J.; Roederer, M.; Koup, R.A.; Bailey, R.T.; Chakrabarti, B.K.; Bailey, M.A.; Gomez, P.L.; et al. A DNA vaccine for ebola virus is safe and immunogenic in a phase i clinical trial. *Clin. Vaccine Immunol.* 2006, 13, 1267–1277.

52. Sullivan, N.J.; Geisbert, T.W.; Geisbert, J.B.; Shedlock, D.J.; Xu, L.; Lamoreaux, L.; Custers, J.H.; Popernack, P.M.; Yang, Z.Y.; Pau, M.G.; et al. Immune protection of nonhuman primates against ebola virus with single low-dose adenovirus vectors encoding modified gps. *PLoS Med.* 2006, 3, e177.

53. Sullivan, N.J.; Sanchez, A.; Rollin, P.E.; Yang, Z.Y.; Nabel, G.J. Development of a preventive vaccine for ebola virus infection in primates. *Nature* 2000, 408, 605–609.

54. Ledgerwood, J.E.; Costner, P.; Desai, N.; Holman, L.; Enama, M.E.; Yamshchikov, G.; Mulangu, S.; Hu, Z.; Andrews, C.A.; Sheets, R.A.; et al. A replication defective recombinant ad5 vaccine expressing ebola virus gp is safe and immunogenic in healthy adults. *Vaccine* 2010, 29, 304–313.

55. Swenson, D.L.; Wang, D.; Luo, M.; Warfield, K.L.; Woraratanadharm, J.; Holman, D.H.; Dong, J.Y.; Pratt, W.D. Vaccine to confer to nonhuman primates complete protection against multistrain ebola and marburg virus infections. *Clin. Vaccine Immunol.* 2008, 15, 460–467.

56. Pratt, W.D.; Wang, D.; Nichols, D.K.; Luo, M.; Woraratanadharm, J.; Dye, J.M.; Holman, D.H.; Dong, J.Y. Protection of nonhuman primates against two species of ebola virus infection with a single complex adenovirus vector. *Clin. Vaccine Immunol.* 2010, 17, 572–581.

57. Richardson, J.S.; Yao, M.K.; Tran, K.N.; Croyle, M.A.; Strong, J.E.; Feldmann, H.; Kobinger, G.P. Enhanced protection against ebola virus mediated by an improved adenovirus-based vaccine. *PLoS One* 2009, 4, e5308.

58. Choi, J.H.; Schafer, S.C.; Zhang, L.; Kobinger, G.P.; Juelich, T.; Freiberg, A.N.; Croyle, M.A. A single sublingual dose of an adenovirus-based vaccine protects against lethal ebola challenge in mice and guinea pigs. *Mol. Pharm.* 2012, 9, 156–167.

59. Geisbert, T.W.; Bailey, M.; Hensley, L.; Asiedu, C.; Geisbert, J.; Stanley, D.; Honko, A.; Johnson, J.; Mulangu, S.; Pau, M.G.; et al. Recombinant adenovirus serotype 26 (ad26) and ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge. *J. Virol.* 2011, 85, 4222–4233.
60. Wagner, R.R.; Rose, J.K. Rhabdoviridae: The Viruses and Their Replication. In Fields Virology; Knipe, D.M., Howley, P.M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 1996; pp. 1121–1135.

61. Geisbert, T.W.; Daddario-Dicaprio, K.M.; Lewis, M.G.; Geisbert, J.B.; Grolla, A.; Leung, A.; Paragas, J.; Matthias, L.; Smith, M.A.; Jones, S.M.; et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008, 4, e1000225.

62. Mire, C.E.; Miller, A.D.; Carville, A.; Westmoreland, S.V.; Geisbert, J.B.; Mansfield, K.G.; Feldmann, H.; Hensley, L.E.; Geisbert, T.W. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl. Trop. Dis. 2012, 6, e1567.

63. Geisbert, T.W.; Geisbert, J.B.; Leung, A.; Daddario-DiCaprio, K.M.; Hensley, L.E.; Grolla, A.; Feldmann, H. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J. Virol. 2009, 83, 7296–7304.

64. Daddario-DiCaprio, K.M.; Geisbert, T.W.; Geisbert, J.B.; Stroher, U.; Hensley, L.E.; Grolla, A.; Fritz, E.A.; Feldmann, F.; Feldmann, H.; Jones, S.M. Cross-protection against marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol. 2006, 80, 9659–9666.

65. Geisbert, T.W.; Daddario-DiCaprio, K.M.; Williams, K.J.; Geisbert, J.B.; Leung, A.; Feldmann, F.; Hensley, L.E.; Feldmann, H.; Jones, S.M. Recombinant vesicular stomatitis virus vector mediates postexposure protection against sudan ebola hemorrhagic fever in nonhuman primates. J. Virol. 2008, 82, 5664–5668.

66. Feldmann, H.; Jones, S.M.; Daddario-DiCaprio, K.M.; Geisbert, J.B.; Stroher, U.; Grolla, A.; Bray, M.; Fritz, E.A.; Fernando, L.; Feldmann, F.; et al. Effective post-exposure treatment of ebola infection. PLoS Pathog. 2007, 3, e2.

67. Gunther, S.; Feldmann, H.; Geisbert, T.W.; Hensley, L.E.; Rollin, P.E.; Nichol, S.T.; Stroher, U.; Artsob, H.; Peters, C.J.; Ksiazek, T.G.; et al. Management of accidental exposure to ebola virus in the biosafety level 4 laboratory, hamburg, germany. J. Infect. Dis. 2011, 204, S785–S790.

68. Blaney, J.E.; Wirblich, C.; Papaneri, A.B.; Johnson, R.F.; Myers, C.J.; Juelich, T.L.; Holbrook, M.R.; Freiber, A.N.; Bernbaum, J.G.; Jahrling, P.B.; et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and ebola viruses. J. Virol. 2011, 85, 10605–10616.

69. Pushko, P.; Parker, M.; Ludwig, G.V.; Davis, N.L.; Johnston, R.E.; Smith, J.F. Replicon-helper systems from attenuated venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239, 389–401.

70. Pushko, P.; Bray, M.; Ludwig, G.V.; Parker, M.; Schmaljohn, A.; Sanchez, A.; Jahrling, P.B.; Smith, J.F. Recombinant rna replicons derived from attenuated venezuelan equine encephalitis virus protect guinea pigs and mice from ebola hemorrhagic fever virus. Vaccine 2000, 19, 142–153.

71. Hevey, M.; Negley, D.; Pushko, P.; Smith, J.; Schmaljohn, A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998, 251, 28–37.
72. Wilson, J.A.; Bray, M.; Bakken, R.; Hart, M.K. Vaccine potential of ebola virus vp24, vp30, vp35, and vp40 proteins. *Virology* 2001, 286, 384–390.

73. Olinger, G.G.; Bailey, M.A.; Dye, J.M.; Bakken, R.; Kuehne, A.; Kondig, J.; Wilson, J.; Hogan, R.J.; Hart, M.K. Protective cytotoxic t-cell responses induced by venezuelan equine encephalitis virus replicons expressing ebola virus proteins. *J. Virol.* 2005, 79, 14189–14196.

74. Bukreyev, A.; Yang, L.; Zaki, S.R.; Shieh, W.J.; Rollin, P.E.; Murphy, B.R.; Collins, P.L.; Sanchez, A. A single intranasal inoculation with a paramyxovirus-vectorized vaccine protects guinea pigs against a lethal-dose ebola virus challenge. *J. Virol.* 2006, 80, 2267–2279.

75. Bukreyev, A.; Rollin, P.E.; Tate, M.K.; Yang, L.; Zaki, S.R.; Shieh, W.J.; Murphy, B.R.; Collins, P.L.; Sanchez, A. Successful topical respiratory tract immunization of primates against ebola virus. *J. Virol.* 2007, 81, 6379–6388.

76. Henrickson, K.J. Parainfluenza viruses. *Clin. Microbiol. Rev.* 2003, 16, 242–264.

77. Bukreyev, A.A.; Dinapoli, J.M.; Yang, L.; Murphy, B.R.; Collins, P.L. Mucosal parainfluenza virus-vectorized vaccine against ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. *Virology* 2010, 399, 290–298.

78. Bukreyev, A.; Huang, Z.; Yang, L.; Elankumaran, S.; St Claire, M.; Murphy, B.R.; Samal, S.K.; Collins, P.L. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. *J. Virol.* 2005, 79, 13275–13284.

79. DiNapoli, J.M.; Nayak, B.; Yang, L.; Finneyfrock, B.W.; Cook, A.; Andersen, H.; Torres-Velez, F.; Murphy, B.R.; Samal, S.K.; Collins, P.L.; Bukreyev, A. Newcastle disease virus-vectorized vaccines expressing the hemagglutinin or neuraminidase protein of h5n1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. *J. Virol.* 2010, 84, 1489–1503.

80. DiNapoli, J.M.; Yang, L.; Samal, S.K.; Murphy, B.R.; Collins, P.L.; Bukreyev, A. Respiratory tract immunization of non-human primates with a newcastle disease virus-vectorized vaccine candidate against ebola virus elicits a neutralizing antibody response. *Vaccine* 2010, 29, 17–25.

81. Jasenosky, L.D.; Neumann, G.; Lukashevich, I.; Kawaoka, Y. Ebola virus vp40-induced particle formation and association with the lipid bilayer. *J. Virol.* 2001, 75, 5205–5214.

82. Licata, J.M.; Johnson, R.F.; Han, Z.; Harty, R.N. Contribution of ebola virus glycoprotein, nucleoprotein, and vp24 to budding of vp40 virus-like particles. *J. Virol.* 2004, 78, 7344–7351.

83. Warfield, K.L.; Swenson, D.L.; Olinger, G.G.; Kalina, W.V.; Aman, M.J.; Bavari, S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal ebola virus challenge. *J. Infect. Dis.* 2007, 196, S430–S437.

84. Swenson, D.L.; Warfield, K.L.; Larsen, T.; Alves, D.A.; Coberley, S.S.; Bavari, S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple marburg viruses. *Expert Rev. Vaccines* 2008, 7, 417–429.

85. Warfield, K.L.; Posten, N.A.; Swenson, D.L.; Olinger, G.G.; Esposito, D.; Gillette, W.K.; Hopkins, R.F.; Costantino, J.; Panchal, R.G.; Hartley, J.L.; et al. Filovirus-like particles produced in insect cells: Immunogenicity and protection in rodents. *J. Infect. Dis.* 2007, 196, S421–S429.

86. Jasenosky, L.D.; Neumann, G.; Lukashevich, I.; Kawaoka, Y. Ebola virus vp40 drives the formation of virus-like filamentous particles along with gp. *J. Virol.* 2002, 76, 4855–4865.
88. Bertolotti-Ciarlet, A.; Ciarlet, M.; Crawford, S.E.; Conner, M.E.; Estes, M.K. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. *Vaccine 2003*, 21, 3885–3900.

89. Li, T.C.; Yamakawa, Y.; Suzuki, K.; Tatsumi, M.; Razak, M.A.; Uchida, T.; Takeda, N.; Miyamura, T. Expression and self-assembly of empty virus-like particles of hepatitis e virus. *J. Virol. 1997*, 71, 7207–7213.

90. Park, J.S.; Oh, Y.K.; Kang, M.J.; Kim, C.K. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 l1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. *J. Med. Virol. 2003*, 70, 633–641.

91. Yao, Q.; Vuong, V.; Li, M.; Compans, R.W. Intranasal immunization with siv virus-like particles (vlps) elicits systemic and mucosal immunity. *Vaccine 2002*, 20, 2537–2545.

92. Sun, Y.; Carrion, R., Jr.; Ye, L.; Wen, Z.; Ro, Y.T.; Brasky, K.; Ticer, A.E.; Schwegler, E.E.; Patterson, J.L.; Compans, R.W.; et al. Protection against lethal challenge by ebola virus-like particles produced in insect cells. *Virology 2009*, 383, 12–21.

93. Ye, L.; Lin, J.; Sun, Y.; Bennouna, S.; Lo, M.; Wu, Q.; Bu, Z.; Pulendran, B.; Compans, R.W.; Yang, C. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. *Virology 2006*, 351, 260–270.

94. Chen, H.; Xu, X.; Jones, I.M. Immunogenicity of the outer domain of a hiv-1 clade c gp120. *Retrovirology 2007*, 4, doi:10.1186/1742-4690-4-33.

95. Guyre, P.M.; Graziano, R.F.; Goldstein, J.; Wallace, P.K.; Morganelli, P.M.; Wardwell, K.; Howell, A.L. Increased potency of fc-receptor-targeted antigens. *Cancer Immunol. Immunother. 1997*, 45, 146–148.

96. Zhang, M.Y.; Wang, Y.; Mankowski, M.K.; Ptak, R.G.; Dimitrov, D.S. Cross-reactive hiv-1-neutralizing activity of serum igg from a rabbit immunized with gp41 fused to iggl fc: Possible role of the prolonged half-life of the immunogen. *Vaccine 2009*, 27, 857–863.

97. Konduru, K.; Bradfute, S.B.; Jacques, J.; Manageeswaran, M.; Nakamura, S.; Morshed, S.; Wood, S.C.; Bavari, S.; Kaplan, G.G. Ebola virus glycoprotein fc fusion protein confers protection against lethal challenge in vaccinated mice. *Vaccine 2011*, 29, 2968–2977.

98. Giddings, G. Transgenic plants as protein factories. *Curr. Opin. Biotechnol. 2001*, 12, 450–454.

99. Hood, E.E.; Woodard, S.L.; Horn, M.E. Monoclonal antibody manufacturing in transgenic plants--myths and realities. *Curr. Opin. Biotechnol. 2002*, 13, 630–635.

100. Huang, Z.; Phoolcharoen, W.; Lai, H.; Piensook, K.; Cardineau, G.; Zeitlin, L.; Whaley, K.J.; Arntzen, C.J.; Mason, H.S.; Chen, Q. High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. *Biotechnol. Bioeng. 2010*, 106, 9–17.

101. Vitale, A.; Pedrazzini, E. Recombinant pharmaceuticals from plants: The plant endomembrane system as bioreactor. *Mol. Interv. 2005*, 5, 216–225.

102. Phoolcharoen, W.; Bhoo, S.H.; Lai, H.; Ma, J.; Arntzen, C.J.; Chen, Q.; Mason, H.S. Expression of an immunogenic ebola immune complex in nicotiana benthamiana. *Plant Biotechnol. J. 2011*, 9, 807–816.

103. Tsuda, Y.; Caposio, P.; Parkins, C.J.; Botto, S.; Messaoudi, I.; Cicin-Sain, L.; Feldmann, H.; Jarvis, M.A. A replicating cytomegalovirus-based vaccine encoding a single ebola virus
nucleoprotein ctl epitope confers protection against ebola virus. *PLoS Negl. Trop. Dis.* **2011**, 5, e1275.

104. Hansen, S.G.; Vieville, C.; Whizin, N.; Coyne-Johnson, L.; Siess, D.C.; Drummond, D.D.; Legasse, A.W.; Axthelm, M.K.; Oswald, K.; Trubey, C.M.; *et al*. Effector memory t cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. *Nat. Med.* **2009**, 15, 293–299.

105. Sylwester, A.W.; Mitchell, B.L.; Edgar, J.B.; Taormina, C.; Pelte, C.; Ruchti, F.; Sleath, P.R.; Grabstein, K.H.; Hosken, N.A.; Kern, F.; *et al*. Broadly targeted human cytomegalovirus-specific cd4+ and cd8+ t cells dominate the memory compartments of exposed subjects. *J. Exp. Med.* **2005**, 202, 673–685.

106. Jarvis, M.A.; Nelson, J.A. Human cytomegalovirus tropism for endothelial cells: Not all endothelial cells are created equal. *J. Virol.* **2007**, 81, 2095–2101.

107. Hansen, S.G.; Ford, J.C.; Lewis, M.S.; Ventura, A.B.; Hughes, C.M.; Coyne-Johnson, L.; Whizin, N.; Oswald, K.; Shoemaker, R.; Swanson, T.; *et al*. Profound early control of highly pathogenic siv by an effector memory t-cell vaccine. *Nature* **2011**, 473, 523–527.

108. Bukreyev, A.; Marzi, A.; Feldmann, F.; Zhang, L.; Yang, L.; Ward, J.M.; Dorward, D.W.; Pickles, R.J.; Murphy, B.R.; Feldmann, H.; *et al*. Chimeric human parainfluenza virus bearing the ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against ebola virus challenge. *Virology* **2009**, 383, 348–361.

109. Geisbert, T.W.; Hensley, L.E.; Jahrling, P.B.; Larsen, T.; Geisbert, J.B.; Paragas, J.; Young, H.A.; Fredeking, T.M.; Rote, W.E.; Vlasuk, G.P. Treatment of ebola virus infection with a recombinant inhibitor of factor viia/tissue factor: A study in rhesus monkeys. *Lancet* **2003**, 362, 1953–1958.

110. Lee, A.; Agnelli, G.; Buller, H.; Ginsberg, J.; Heit, J.; Rote, W.; Vlasuk, G.; Costantini, L.; Julian, J.; Comp, P.; *et al*. Dose-response study of recombinant factor viia/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. *Circulation* **2001**, 104, 74–78.

111. Moons, A.H.; Peters, R.J.; Bijsterveld, N.R.; Piek, J.J.; Prins, M.H.; Vlasuk, G.P.; Rote, W.E.; Buller, H.R. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor viia complex, in patients undergoing elective coronary angioplasty. *J. Am. Coll. Cardiol.* **2003**, 41, 2147–2153.

112. Geisbert, T.W.; Daddario-DiCaprio, K.M.; Geisbert, J.B.; Young, H.A.; Formenty, P.; Fritz, E.A.; Larsen, T.; Hensley, L.E. Marburg virus angola infection of rhesus macaques: Pathogenesis and treatment with recombinant nematode anticoagulant protein c2. *J. Infect. Dis.* **2007**, 196, S372–S381.

113. Lebleu, B.; Moulton, H.M.; Abes, R.; Ivanova, G.D.; Abes, S.; Stein, D.A.; Iversen, P.L.; Arzumanov, A.A.; Gait, M.J. Cell penetrating peptide conjugates of steric block oligonucleotides. *Adv. Drug Deliv. Rev.* **2008**, 60, 517–529.
116. Iversen, P.L. Phosphorodiamidate morpholino oligomers: Favorable properties for sequence-specific gene inactivation. *Curr. Opin. Mol. Ther.* 2001, 3, 235–238.

117. Summerton, J.; Weller, D. Morpholino antisense oligomers: Design, preparation, and properties. *Antisense Nucleic Acid Drug Dev.* 1997, 7, 187–195.

118. Youngblood, D.S.; Hatlevig, S.A.; Hassinger, J.N.; Iversen, P.L.; Moulton, H.M. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. *Bioconjug. Chem.* 2007, 18, 50–60.

119. Kinney, R.M.; Huang, C.Y.; Rose, B.C.; Kroeker, A.D.; Dreher, T.W.; Iversen, P.L.; Stein, D.A. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. *J. Virol.* 2005, 79, 5116–5128.

120. Neuman, B.W.; Stein, D.A.; Kroeker, A.D.; Churchill, M.J.; Kim, A.M.; Kuhn, P.; Dawson, P.; Moulton, H.M.; Bestwick, R.K.; Iversen, P.L.; et al. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. *J. Virol.* 2005, 79, 9665–9676.

121. Enterlein, S.; Warfield, K.L.; Swenson, D.L.; Stein, D.A.; Smith, J.L.; Gamble, C.S.; Kroeker, A.D.; Iversen, P.L.; Bavari, S.; Muhlberger, E. Vp35 knockdown inhibits ebola virus amplification and protects against lethal infection in mice. *Antimicrob. Agents Chemother.* 2006, 50, 984–993.

122. Swenson, D.L.; Warfield, K.L.; Warren, T.K.; Lovejoy, C.; Hassinger, J.N.; Ruthel, G.; Blouch, R.E.; Moulton, H.M.; Weller, D.D.; Iversen, P.L.; et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against ebola virus infection. *Antimicrob. Agents Chemother.* 2009, 53, 2089–2099.

123. Warren, T.K.; Warfield, K.L.; Wells, J.; Swenson, D.L.; Donner, K.S.; van Tongeren, S.A.; Garza, N.L.; Dong, L.; Mourich, D.V.; Crumley, S.; et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. *Nat. Med.* 2010, 16, 991–994.

124. Bray, M.; Mahanty, S. Ebola hemorrhagic fever and septic shock. *J. Infect. Dis.* 2003, 188, 1613–1617.

125. Hensley, L.E.; Stevens, E.L.; Yan, S.B.; Geisbert, J.B.; Macias, W.L.; Larsen, T.; Daddario-DiCaprio, K.M.; Cassell, G.H.; Jahrling, P.B.; Geisbert, T.W. Recombinant human activated protein c for the postexposure treatment of ebola hemorrhagic fever. *J. Infect. Dis.* 2007, 196, S390–S399.

126. Schnittler, H.J.; Feldmann, H. Marburg and ebola hemorrhagic fevers: Does the primary course of infection depend on the accessibility of organ-specific macrophages? *Clin. Infect. Dis.* 1998, 27, 404–406.

127. Macias, W.L.; Nelson, D.R. Severe protein c deficiency predicts early death in severe sepsis. *Crit. Care Med.* 2004, 32, S223–S228.

128. Shorr, A.F.; Bernard, G.R.; Dhainaut, J.F.; Russell, J.R.; Macias, W.L.; Nelson, D.R.; Sundin, D.P. Protein c concentrations in severe sepsis: An early directional change in plasma levels predicts outcome. *Crit. Care* 2006, 10, R92.

129. Bernard, G.R.; Vincent, J.L.; Laterre, P.F.; LaRosa, S.P.; Dhainaut, J.F.; Lopez-Rodriguez, A.; Steinrub, J.S.; Garber, G.E.; Helterbrand, J.D.; Ely, E.W.; et al. Efficacy and safety of recombinant human activated protein c for severe sepsis. *N. Engl. J. Med.* 2001, 344, 699–709.
130. Geisbert, T.W.; Young, H.A.; Jahrling, P.B.; Davis, K.J.; Kagan, E.; Hensley, L.E. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. *J. Infect. Dis.* **2003**, *188*, 1618–1629.

131. Colbere-Garapin, F.; Blondel, B.; Saulnier, A.; Pelletier, I.; Labadie, K. Silencing viruses by rna interference. *Microbes Infect.* **2005**, *7*, 767–775.

132. Tan, F.L.; Yin, J.Q. Rnai, a new therapeutic strategy against viral infection. *Cell Res.* **2004**, *14*, 460–466.

133. Sanchez, A.B.; Perez, M.; Cornu, T.; de la Torre, J.C. Rna interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. *J. Virol.* **2005**, *79*, 11071–11081.

134. Wu, C.J.; Huang, H.W.; Liu, C.Y.; Hong, C.F.; Chan, Y.L. Inhibition of sars-cov replication by sirna. *Antiviral. Res.* **2005**, *65*, 45–48.

135. Fowler, T.; Bamberg, S.; Moller, P.; Klenk, H.D.; Meyer, T.F.; Becker, S.; Rudel, T. Inhibition of marburg virus protein expression and viral release by rna interference. *J. Gen. Virol.* **2005**, *86*, 1181–1188.

136. Wu, S.Y.; McMillan, N.A. Lipidic systems for in vivo sirna delivery. *AAPS J.* **2009**, *11*, 639–652.

137. Geisbert, T.W.; Hensley, L.E.; Kagan, E.; Yu, E.Z.; Geisbert, J.B.; Daddario-DiCaprio, K.; Fritz, E.A.; Jahrling, P.B.; McClintock, K.; Phelps, J.R.; et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by rna interference. *J. Infect. Dis.* **2006**, *193*, 1650–1657.

138. Geisbert, T.W.; Lee, A.C.; Robbins, M.; Geisbert, J.B.; Honko, A.N.; Sood, V.; Johnson, J.C.; de Jong, S.; Tavakoli, I.; Judge, A.; et al. Postexposure protection of non-human primates against a lethal ebola virus challenge with rna interference: A proof-of-concept study. *Lancet* **2010**, *375*, 1896–1905.

139. Morrissey, D.V.; Lockridge, J.A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V.; et al. Potent and persistent in vivo anti-hbv activity of chemically modified sirnas. *Nat. Biotechnol.* **2005**, *23*, 1002–1007.

140. Michelow, I.C.; Lear, C.; Scully, C.; Prugar, L.I.; Longley, C.B.; Yantosca, L.M.; Ji, X.; Karpel, M.; Brudner, M.; Takahashi, K.; et al. High-dose mannose-binding lectin therapy for ebola virus infection. *J. Infect. Dis.* **2011**, *203*, 175–179.

141. Petersen, K.A.; Matthiesen, F.; Agger, T.; Kongerslev, L.; Thiel, S.; Cornelissen, K.; Axelsen, M. Phase i safety, tolerability, and pharmacokinetic study of recombinant human mannann-binding lectin. *J. Clin. Immunol.* **2006**, *26*, 465–475.

142. Ji, X.; Olinger, G.G.; Aris, S.; Chen, Y.; Gewurz, H.; Spear, G.T. Mannose-binding lectin binds to ebola and marburg envelope glycoproteins, resulting in blocking of virus interaction with design and complement-mediated virus neutralization. *J. Gen. Virol.* **2005**, *86*, 2535–2542.

143. Bugni, T.S.; Richards, B.; Bhoite, L.; Cimbora, D.; Harper, M.K.; Ireland, C.M. Marine natural product libraries for high-throughput screening and rapid drug discovery. *J. Nat. Prod.* **2008**, *71*, 1095–1098.
144. Li, X.; Yang, J.; He, X.; Yang, Z.; Ding, Y.; Zhao, P.; Liu, Z.; Shao, H.; Li, Z.; Zhang, Y.; Si, S. Identification of upregulators of bmp2 expression via high-throughput screening of a synthetic and natural compound library. *J. Biomol. Screen* **2009**, *14*, 1251–1256.

145. Xie, Q.; Matsunaga, S.; Wen, Z.; Niimi, S.; Kumano, M.; Sakakibara, Y.; Machida, S. *In vitro* system for high-throughput screening of random peptide libraries for antimicrobial peptides that recognize bacterial membranes. *J. Pept. Sci.* **2006**, *12*, 643–652.

146. Shum, D.; Smith, J.L.; Hirsch, A.J.; Bhinder, B.; Radu, C.; Stein, D.A.; Nelson, J.A.; Fruh, K.; Djaballah, H. High-content assay to identify inhibitors of dengue virus infection. *Assay Drug Dev. Technol.* **2010**, *8*, 553–570.

147. Payne, D.J.; Gwynn, M.N.; Holmes, D.J.; Pompliano, D.L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. *Nat. Rev. Drug Discov.* **2007**, *6*, 29–40.

148. Warren, T.K.; Warfield, K.L.; Wells, J.; Enterlein, S.; Smith, M.; Ruthel, G.; Yunus, A.S.; Kinch, M.S.; Goldblatt, M.; Aman, M.J.; *et al.* Antiviral activity of a small-molecule inhibitor of filovirus infection. *Antimicrob. Agents Chemother.* **2010**, *54*, 2152–2159.

149. Aman, M.J.; Kinch, M.S.; Warfield, K.; Warren, T.; Yunus, A.; Enterlein, S.; Stavale, E.; Wang, P.; Chang, S.; Tang, Q.; *et al.* Development of a broad-spectrum antiviral with activity against ebola virus. *Antiviral Res.* **2009**, *83*, 245–251.

150. Panchal, R.G.; Kota, K.P.; Spurgers, K.B.; Ruthel, G.; Tran, J.P.; Boltz, R.C.; Bavari, S. Development of high-content imaging assays for lethal viral pathogens. *J. Biomol. Screen* **2010**, *15*, 755–765.

151. Panchal, R.G.; Reid, S.P.; Tran, J.P.; Bergeron, A.A.; Wells, J.; Kota, K.P.; Aman, J.; Bavari, S. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. *Antiviral Res.* **2012**, *93*, 23–29.

152. Chang, E.L.; Olinger, G.G.; Hensley, L.E.; Lear, C.M.; Scully, C.E.; Mankowski, M.K.; Ptak, R.G.; Thach, D.C.; Knight, D.A. Hexamminecobalt (iii) chloride as a broad-spectrum antiviral complex. *J. Antivir. Antiretrovir.* **2011**, *3*, 020–027.

153. Carstea, E.D.; Morris, J.A.; Coleman, K.G.; Loftus, S.K.; Zhang, D.; Cummings, C.; Gu, J.; Rosenfeld, M.A.; Pavan, W.J.; Krizman, D.B.; *et al.* Niemann-pick c1 disease gene: Homology to mediators of cholesterol homeostasis. *Science* **1997**, *277*, 228–231.

154. Goldman, S.D.; Krise, J.P. Niemann-pick c1 functions independently of niemann-pick c2 in the initial stage of retrograde transport of membrane-impermeable lysosomal cargo. *J. Biol. Chem.* **2010**, *285*, 4983–4994.

155. Lloyd-Evans, E.; Morgan, A.J.; He, X.; Smith, D.A.; Elliot-Smith, E.; Sillence, D.J.; Churchill, G.C.; Schuchman, E.H.; Galione, A.; Platt, F.M. Niemann-pick disease type c1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. *Nat. Med.* **2008**, *14*, 1247–1255.

156. Tang, Y.; Leao, I.C.; Coleman, E.M.; Broughton, R.S.; Hildreth, J.E. Deficiency of niemann-pick type c-1 protein impairs release of human immunodeficiency virus type 1 and results in gag accumulation in late endosomal/lysosomal compartments. *J. Virol.* **2009**, *83*, 7982–7995.

157. Cenedella, R.J. Cholesterol synthesis inhibitor ul8666a and the role of sterol metabolism and trafficking in numerous pathophysiological processes. *Lipids* **2009**, *44*, 477–487.
158. Smith, D.R.; McCarthy, S.; Chrovian, A.; Olinger, G.; Stossel, A.; Geisbert, T.W.; Hensley, L.E.; Connor, J.H. Inhibition of heat-shock protein 90 reduces ebola virus replication. *Antivir. Res.* **2010**, *87*, 187–194.

159. Pratt, W.B.; Toft, D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. *Exp. Biol. Med. (Maywood)* **2003**, *228*, 111–133.

160. Goetz, M.P.; Toft, D.; Reid, J.; Ames, M.; Stensgard, B.; Safgren, S.; Adjei, A.A.; Sloan, J.; Atherton, P.; Vasile, V.; *et al.* Phase i trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. *J. Clin. Oncol.* **2005**, *23*, 1078–1087.

161. Whitesell, L.; Lindquist, S.L. Hsp90 and the chaperoning of cancer. *Nat. Rev. Cancer* **2005**, *5*, 761–772.

162. Connor, J.H.; McKenzie, M.O.; Parks, G.D.; Lyles, D.S. Antiviral activity and rna polymerase degradation following hsp90 inhibition in a range of negative strand viruses. *Virolology* **2007**, *362*, 109–119.

163. Geller, R.; Vignuzzi, M.; Andino, R.; Frydman, J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. *Genes Dev.* **2007**, *21*, 195–205.

164. Hung, J.J.; Chung, C.S.; Chang, W. Molecular chaperone hsp90 is important for vaccinia virus growth in cells. *J. Virol.* **2002**, *76*, 1379–1390.

165. Ujino, S.; Yamaguchi, S.; Shimotohno, K.; Takaku, H. Heat-shock protein 90 is essential for stabilization of the hepatitis c virus nonstructural protein ns3. *J. Biol. Chem.* **2009**, *284*, 6841–6846.

166. Radoshitzky, S.R.; Warfield, K.L.; Chi, X.; Dong, L.; Kota, K.; Bradfute, S.B.; Gearhart, J.D.; Retterer, C.; Kranzusch, P.J.; Misasi, J.N.; *et al.* Ebola virus delta-peptide immunoadesins inhibit marburgvirus and ebolavirus cell entry. *J. Virol.* **2011**, *85*, 8502–8513.

167. Wahl-Jensen, V.M.; Afanasieva, T.A.; Seebach, J.; Stroher, U.; Feldmann, H.; Schnittler, H.J. Effects of ebola virus glycoproteins on endothelial cell activation and barrier function. *J. Virol.* **2005**, *79*, 10442–10450.

168. Ujike, M.; Nishikawa, H.; Otaka, A.; Yamamoto, N.; Matsuoka, M.; Kodama, E.; Fujii, N.; Taguchi, F. Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. *J. Virol.* **2008**, *82*, 588–592.

169. Wild, C.T.; Shugars, D.C.; Greenwell, T.K.; McDanal, C.B.; Matthews, T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 9770–9774.

170. Chan, D.C.; Chutkowski, C.T.; Kim, P.S. Evidence that a prominent cavity in the coiled coil of hiv type 1 gp41 is an attractive drug target. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 15613–15617.

171. Furuta, R.A.; Wild, C.T.; Weng, Y.; Weiss, C.D. Capture of an early fusion-active conformation of hiv-1 gp41. *Nat. Struct. Biol.* **1998**, *5*, 276–279.

172. Miller, E.H.; Harrison, J.S.; Radoshitzky, S.R.; Higgins, C.D.; Chi, X.; Dong, L.; Kuhn, J.H.; Bavari, S.; Lai, J.R.; Chandran, K. Inhibition of ebola virus entry by a c-peptide targeted to endosomes. *J. Biol. Chem.* **2011**, *286*, 15854–15861.
173. Gump, J.M.; Dowdy, S.F. Tat transduction: The molecular mechanism and therapeutic prospects. *Trends Mol. Med.* 2007, 13, 443–448.

174. Richard, J.P.; Melikov, K.; Brooks, H.; Prevot, P.; Lebleu, B.; Chernomordik, L.V. Cellular uptake of unconjugated tat peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. *J. Biol. Chem.* 2005, 280, 15300–15306.

175. Guo, H.; Pan, X.; Mao, R.; Zhang, X.; Wang, L.; Lu, X.; Chang, J.; Guo, J.T.; Passic, S.; Krebs, F.C.; *et al*. Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses. *Antimicrob. Agents Chemother.* 2011, 55, 478–486.

176. Basu, A.; Li, B.; Mills, D.M.; Panchal, R.G.; Cardinale, S.C.; Butler, M.M.; Peet, N.P.; Majgier-Baranowska, H.; Williams, J.D.; Patel, I.; *et al*. Identification of a small-molecule entry inhibitor for filoviruses. *J. Virol.* 2011, 85, 3106–3119.

177. Wolf, M.C.; Freiberger, A.N.; Zhang, T.; Akyol-Ataman, Z.; Grock, A.; Hong, P.W.; Li, J.; Watson, N.F.; Fang, A.Q.; Aguilar, H.C.; *et al*. A broad-spectrum antiviral targeting entry of enveloped viruses. *Proc. Natl. Acad. Sci. USA* 2010, 107, 3157–3162.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).